AA
YARW

AlphaCentric Advisors’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

AlphaCentric Advisors’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,370
Closed -$505K – 286
2024
Q3 		$505K Sell
5,370
-840
-14% -$79.6K 0.38% 74
2024
Q2 		$612K Sell
6,210
-2,690
-30% -$335K 0.45% 71
2024
Q1 		$1.37M Sell
8,900
-4,463
-33% -$481K 0.82% 47
2023
Q4 		$1.56M Buy
+13,363
New +$2.08M 1.05% 32

Other funds holding YARW

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AlphaCentric Advisors's YARW Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q4 2024, closing a stake of 5,370 shares — an estimated $505K sold.

AlphaCentric Advisors first reported a position in YARW in Q4 2023 and held it in 4 quarters. The position peaked at $1.56M in Q4 2023. 34 funds tracked by Wall St. Rank hold YARW as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 5,370 Yarrow Bioscience, Inc. Common Stock shares in Q4 2024, an estimated $505K.
  • AlphaCentric Advisors first reported a position in Yarrow Bioscience, Inc. Common Stock in Q4 2023 and held it in 4 quarters.
  • AlphaCentric Advisors's Yarrow Bioscience, Inc. Common Stock position peaked at $1.56M in Q4 2023.
  • 34 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.